{"id":13901,"date":"2022-11-25T10:08:00","date_gmt":"2022-11-25T10:08:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3947010_AE47010_0"},"modified":"2022-11-25T10:08:00","modified_gmt":"2022-11-25T10:08:00","slug":"venus-medtech-to-showcase-its-structural-heart-treatments-at-london-valves-2022","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=13901","title":{"rendered":"Venus Medtech to showcase its structural heart treatments at London Valves 2022"},"content":{"rendered":"
<\/div>\n
\n

The company’s growing number of solutions for structural heart disease will be presented at multiple events during the conference between November 27-29<\/span> <\/i><\/p>\n

HANGZHOU, China<\/span>, Nov. 25, 2022<\/span> \/PRNewswire\/ — Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The company will present its products at the conference taking place at the ExCeL London November 27-29, 2022<\/span> in its booth (#25), during a symposium, and at the official launch of the TARGET multicenter clinical study.<\/p>\n

Structural heart symposium on November 27<\/span> <\/b><\/p>\n

The company will also be hosting a symposium on November 27<\/span> (Hall #4 at 17:30 pm<\/span>) where top investigators will discuss the latest results and future plans for the Venus Medtech tricuspid and pulmonary valve replacement systems. During this symposium, “The Right Valves for The Right Ventricle: Venus MedTech tricuspid and pulmonary replacement systems,”<\/i> interventional cardiologists will have the opportunity to learn the latest about structural heart interventions.<\/p>\n

Launch of TARGET CE Study for tricuspid valve replacement on November 28<\/span><\/b><\/p>\n

Additionally, Venus Medtech will be officially launching the TARGET study at the conference. The TARGET study will evaluate the safety and performance of the Cardiovalve Tricuspid System\u2014with its associated procedure\u2014in reducing tricuspid regurgitation and the associated symptoms. The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter approach. The study will enroll one hundred patients in up to thirty medical centers. Patients will be followed for a period of up to five years.<\/p>\n

The TARGET CE Study will be launched officially at the Sunborn London Yacht Hotel on Monday, November 28<\/span> at 18:30 pm<\/span>.<\/p>\n

Presentation of new data <\/b><\/p>\n

The experiences with Cardiovalve and presentation of new data will be held in the following sessions:<\/p>\n